Despite recent advances in radiotherapy and chemotherapy, survival rates for squamous
cell carcinoma of the head and neck (SCCHN) have remained poor. The focus of SCCHN …

Purpose This study describes the long-term survival and toxicity outcomes of a multicenter
randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or …

Background Postoperative cisplatin and radiation is the standard of care for high‐risk
squamous cell carcinoma of the head and neck (SCCHN). We have used cetuximab and …

6043 Background: C-mab is a monoclonal antibody targeting EGFR. C-mab combined with
radiotherapy (RT) improved loco-regional control and overall survival over RT alone in HNC …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

Purpose To determine the potential efficacy of combining cetuximab with chemotherapy in
patients with advanced nodal disease, we conducted a phase II trial with induction …

Head and neck cancer is a challenging disease. The treatment is quite complex and
significant toxicity is seen with the combination of chemotherapy, radiation therapy and …

Abstract Treatment options for locally advanced squamous cell carcinoma of the head and
neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or …

5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …

Since the introduction of Cetuximab as a biological molecule against Epidermal Growth
Factor Receptor (EGFR), its use in the cancers of head and neck region is widely explored …